Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20040082620 A1
Publication typeApplication
Application numberUS 10/451,215
PCT numberPCT/GB2001/005751
Publication dateApr 29, 2004
Filing dateDec 21, 2001
Priority dateDec 22, 2000
Also published asCN1310912C, CN1491224A, DE60122580D1, DE60122580T2, EP1349855A1, EP1349855B1, US7291740, US20060040993, WO2002051839A1
Publication number10451215, 451215, PCT/2001/5751, PCT/GB/1/005751, PCT/GB/1/05751, PCT/GB/2001/005751, PCT/GB/2001/05751, PCT/GB1/005751, PCT/GB1/05751, PCT/GB1005751, PCT/GB105751, PCT/GB2001/005751, PCT/GB2001/05751, PCT/GB2001005751, PCT/GB200105751, US 2004/0082620 A1, US 2004/082620 A1, US 20040082620 A1, US 20040082620A1, US 2004082620 A1, US 2004082620A1, US-A1-20040082620, US-A1-2004082620, US2004/0082620A1, US2004/082620A1, US20040082620 A1, US20040082620A1, US2004082620 A1, US2004082620A1
InventorsAndrew Craig, Tim Ho, Michael Millan, Deirdre O'Keeffe
Original AssigneeCraig Andrew Simon, Ho Tim Chien Ting, Michael Millan, O'keeffe Deirdre
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
5'-4-'2-(n-methyl-n-(2-pyridyl)amino)ethoxy!benzyl!thiazolidine-2, 4-dione mesylate salt
US 20040082620 A1
Abstract
Disclosed are 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione mesylate salts, or solvates thereof; processes for preparing such compounds, compositions comprising such compounds and the use of such compounds in medicine.
Images(13)
Previous page
Next page
Claims(17)
1. A compound 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione mesylate salt, or solvate thereof.
2. A compound according to claim 1, in the form of a novel polymorph.
3. A compound according to claim 1 or claim 2, characterised by data provided by at least one of the following: infra red, Raman, X-ray or nuclear magnetic resonance and melting point data, as provided herein, including partial spectral data provided herein
4. A compound according to any one of claims 1 to 3, being Mesylate Form I, Mesylate Form II, Mesylate Form III or Mesylate Form IV, or a solvate thereof.
5. A compound according to any one of claims 1 to 3, being Mesylate Form I characterised by
(i) an infra red spectrum containing peaks at about 1515, 670, 606 cm−1; and/or
(ii) a Raman spectrum containing peaks at about 887, 671 cm−1; and/or
(iii) an X-ray powder diffraction (XRPD) pattern containing peaks at about 17.4, 19.6, 20.0, 28.5°2θ.
6. A compound according to any one of claims 1 to 3, being Mesylate Form II, characterised by
(i) an infra red spectrum containing peaks at about 674, 609 cm−1; and/or
(ii) a Raman spectrum containing peaks at about 883, 609 cm−1; and/or
(iii) an X-ray powder diffraction (XRPD) pattern containing peaks at about 20.2, 28.0, 28.8, 29.5°2θ.
7. A compound according to any one of claims 1 to 3, being Mesylate Form III, characterised by
(i) an infra red spectrum containing peaks at about 1206, 603, 559, 545 cm−1; and/or
(ii) a Raman spectrum containing peaks at about 1205, 1179, 657, 557 cm−1; and/or
(iii) an X-ray powder diffraction (XRPD) pattern containing peaks at about 7.7, 14.8, 15.4, 16.9, 32.9°2θ.
8. A compound according to any one of claims 1 to 3, Mesylate Form IV, characterised by
(i) an infra red spectrum containing peaks at about 1549, 759, 600 cm−1; and/or
(ii) a Raman spectrum containing peaks at about 1338, 1183, 990, 552 cm−1; and/or
(iii) an X-ray powder diffraction (XRPD) pattern containing peaks at about 6.2, 11.9, 15.9, 19.8, 22.7°2θ.
9. A compound according to claim 7, being Mesylate Form IV, characterised in that it provides:
(i) an infrared spectrum substantially in accordance with FIG. 1; and
(ii) a Raman spectrum substantially in accordance with FIG. 2; and
(iii) an X-Ray powder diffraction pattern (XRPD) substantially in accordance with Table 1 or FIG. 3; and
(iv) a Solid State 13C NMR spectrum substantially in accordance with FIG. 4.
10. A compound according to any one of claims 1 to 9, in pure form.
11. A compound according to any one of claims 1 to 10, in crystalline form.
12. A compound according to any one of claims 1 to 10, in a solid pharmaceutically acceptable form.
13. A process for preparing 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione mesylate salt, or solvate thereof. (“the Mesylate”) or a solvate thereof, characterised in that 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (Compound (I)), or a salt thereof, dispersed or dissolved in a solvent, is reacted with a source of mesylate ion and thereafter, if required, a solvate of the resulting Mesylate is prepared; and the Mesylate or a solvate thereof is recovered.
14. A pharmaceutical composition comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione mesylate salt (“the Mesylate”) or solvate thereof, according to claim 1, and a pharmaceutically acceptable carrier therefor.
15. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione mesylate salt (“the Mesylate”) or solvate thereof, according to claim 1, for use as an active therapeutic substance.
16. The use of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione mesylate salt (“the Mesylate”) or solvate thereof, according to claim 1, for the manufacture of a medicament for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.
17. A method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a human or non-human mammal which comprises administering an effective, non-toxic, amount of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione mesylate salt (“the Mesylate”) or solvate thereof, according to claim 1, to a human or non-human mammal in need thereof.
Description
  • [0001]
    This invention relates to a novel pharmaceutical, to a process for the preparation of the pharmaceutical and to the use of the pharmaceutical in medicine.
  • [0002]
    EP-A-0 306 228 relates to certain thiazolidinedione derivatives disclosed as having hypoglycaemic and hypolipidaemic activity. The compound of Example 30 of EP-A-0 306 228 is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (hereinafter referred to as “Compound (I)”).
  • [0003]
    WO 94/05659 discloses certain salts of the compounds of EP-A-0 306 228. The preferred salt of WO 94/05659 is the maleic acid salt. Methanesulfonic acid is mentioned as a potential counter-ion but the preparation of a methanesulfonic acid salt is not exemplified.
  • [0004]
    We have now prepared and characterised a methanesulfonate salt of Compound (I) and discovered that a novel form of methanesulfonate salt (hereinafter also referred to as the “Mesylate”) is formed that is particularly stable and hence is suitable for bulk preparation and handling. The Mesylate also has a high melting point, shows particularly good aqueous solubility and possesses good bulk flow properties. The Mesylate is therefore surprisingly amenable to large scale pharmaceutical processing and especially to large scale milling.
  • [0005]
    The novel salt can be prepared by an efficient and economic process particularly suited to large-scale preparation.
  • [0006]
    The novel Mesylate also has useful pharmaceutical properties and in particular it is indicated to be useful for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.
  • [0007]
    Accordingly, the present invention provides 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione mesylate salt, or solvate thereof.
  • [0008]
    It has been found that the Mesylate exists in more than one novel polymorphic form. The present invention extends to all such forms whether in a pure polymorphic form or when admixed with any other material, such as another polymorphic form. Herein, the novel polymorpic forms of the Mesylate are referred to as Form I, Form II, Form III and Form IV. Each of the said forms may also be referred to herein as the Mesylate as appropriate.
  • [0009]
    Suitably, the invention provides the Mesylate, or a solvate thereof, suitably as characterised by data provided by at least one of the following: infrared, Raman, X-ray powder diffraction or nuclear magnetic resonance and melting point data as provided herein, including partial spectral data provided herein
  • [0010]
    In a further aspect the invention provides Mesylate Form I, or solvate thereof.
  • [0011]
    In a further aspect the invention provides Mesylate Form II, or solvate thereof.
  • [0012]
    In a further aspect the invention provides Mesylate Form m, or solvate thereof.
  • [0013]
    In a preferred aspect the invention provides Mesylate Form IV, or solvate thereof.
  • [0014]
    In a particular aspect, the present invention provides 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione mesylate salt (Form I), characterised by
  • [0015]
    (i) an infrared spectrum containing peaks at about 1515, 670, 606 cm−1; and/or
  • [0016]
    (ii) a Raman spectrum containing peaks at about 887, 671 cm1; and/or
  • [0017]
    (iii) an X-ray powder diffraction (XRPD) pattern containing peaks at about 17.4, 19.6, 20.0, 28.5°2θ.
  • [0018]
    Depending on the solvent from which the Mesylate is recovered, the Mesylate may be obtained as a solvate, and such solvate is a favoured aspect of the invention.
  • [0019]
    In one favoured aspect, the Mesylate provides an infrared spectrum substantially in accordance with FIG. 1.
  • [0020]
    In one favoured aspect, the Mesylate provides a Raman spectrum substantially in accordance with FIG. 2.
  • [0021]
    In one favoured aspect, the Mesylate provides an X-Ray powder diffraction pattern (XRPD) substantially in accordance with Table 1 or FIG. 3.
  • [0022]
    In a particular aspect, the present invention provides 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione mesylate salt (Form II), characterised by
  • [0023]
    (i) an infrared spectrum containing peaks at about 674, 609 cm−1; and/or
  • [0024]
    (ii) a Raman spectrum containing peaks at about 883, 609 cm−1; and/or
  • [0025]
    (iii) an X-ray powder diffraction (XRPD) pattern containing peaks at about 20.2, 28.0, 28.8, 29.5°2θ.
  • [0026]
    Depending on the solvent from which the Mesylate is recovered, the Mesylate may be obtained as a solvate, and such solvate is a favoured aspect of the invention.
  • [0027]
    In one favoured aspect, the Mesylate provides an infrared spectrum substantially in accordance with FIG. 4.
  • [0028]
    In one favoured aspect, the Mesylate provides a Raman spectrum substantially in accordance with FIG. 5.
  • [0029]
    In one favoured aspect, the Mesylate provides an X-Ray powder diffraction pattern (XRPD) substantially in accordance with Table 2 or FIG. 6.
  • [0030]
    In a particular aspect, the present invention provides 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione mesylate salt (Form III), characterised by
  • [0031]
    (i) an infrared spectrum containing peaks at about 1206, 603, 559, 545 cm−1; and/or
  • [0032]
    (ii) a Raman spectrum containing peaks at about 1205, 1179, 657, 557 cm 1; and/or
  • [0033]
    (iii) an X-ray powder diffraction (XRPD) pattern containing peaks at about 7.7, 14.8, 15.4, 16.9, 32.9°2θ.
  • [0034]
    Depending on the solvent from which the Mesylate is recovered, the Mesylate may be obtained as a solvate, and such solvate is a favoured aspect of the invention.
  • [0035]
    In one favoured aspect, the Mesylate provides an infrared spectrum substantially in accordance with FIG. 7.
  • [0036]
    In one favoured aspect, the Mesylate provides a Raman spectrum substantially in accordance with FIG. 8.
  • [0037]
    In one favoured aspect, the Mesylate provides an X-Ray powder diffraction pattern (XRPD) substantially in accordance with Table 3 or FIG. 9.
  • [0038]
    In one particular aspect, the present invention provides 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione mesylate salt (Form IV), characterised by
  • [0039]
    (i) an infrared spectrum containing peaks at about 1549, 759, 600 cm−1; and/or
  • [0040]
    (ii) a Raman spectrum containing peaks at about 1338, 1183, 990, 552 cm−1; and/or
  • [0041]
    (iii) an X-ray powder diffraction (XRPD) pattern containing peaks at about 6.2, 11.9, 15.9, 19.8, 22.7°2θ.
  • [0042]
    Depending on the solvent from which the Mesylate is recovered, the Mesylate may be obtained as a solvate, and such solvate is a favoured aspect of the invention.
  • [0043]
    In one favoured aspect, the Mesylate provides an infrared spectrum substantially in accordance with FIG. 10.
  • [0044]
    In one favoured aspect, the Mesylate provides a Raman spectrum substantially in accordance with FIG. 11.
  • [0045]
    In one favoured aspect, the Mesylate provides an X-Ray powder diffraction pattern (XRPD) substantially in accordance with Table 4 or FIG. 12.
  • [0046]
    In one favoured aspect, the Mesylate provides a Solid State 13C NMR spectrum substantially in accordance with FIG. 13.
  • [0047]
    In a further favoured aspect the Mesylate Form IV, provides a melting range in the range of 142 to 152° C., for example 148.9-150.3° C.
  • [0048]
    In a most preferred aspect, the invention provides 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, Mesylate salt Form IV, characterised in that it provides:
  • [0049]
    (i) an infrared spectrum substantially in accordance with FIG. 10; and
  • [0050]
    (ii) a Raman spectrum substantially in accordance with FIG. 11; and
  • [0051]
    (iii) an X-Ray powder diffraction pattern (XRPD) substantially in accordance with Table 4 or FIG. 12; and
  • [0052]
    (iv) a Solid State 13C NMR spectrum substantially in accordance with FIG. 13.
  • [0053]
    The present invention encompasses the Mesylate or a solvate thereof isolated in pure form or when admixed with other materials.
  • [0054]
    Thus in one aspect there is provided the Mesylate or a solvate thereof in isolated form.
  • [0055]
    In a further aspect there is provided the Mesylate or a solvate thereof in pure form.
  • [0056]
    In yet a further aspect there is provided the Mesylate or a solvate thereof in crystalline form.
  • [0057]
    Also, the invention provides the Mesylate or solvate thereof in a solid pharmaceutically acceptable form, such as a solid dosage form, especially when adapted for oral administration.
  • [0058]
    Moreover, the invention also provides the Mesylate or solvate thereof in a pharmaceutically acceptable form, especially in bulk form, such form being particularly capable of being milled. The invention therefor also provides the Mesylate or solvate thereof in a milled form.
  • [0059]
    Furthermore, the invention provides the Mesylate or solvate thereof in a pharmaceutically acceptable form, especially in bulk form, such form having good flow properties, especially good bulk flow properties.
  • [0060]
    A suitable solvate is a a pharmaceutically acceptable solvate, such as a hydrate.
  • [0061]
    The invention also provides a process for preparing the Mesylate or a solvate thereof, characterised in that 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (Compound (1)), or a salt thereof, preferably dispersed or dissolved in a suitable solvent, is reacted with a suitable source of mesylate ion and thereafter, if required, a solvate of the resulting Mesylate is prepared; and the Mesylate or a solvate thereof is recovered.
  • [0062]
    Conveniently, the source of Mesylate ion is methanesulfonic acid. The methanesulfonic acid is preferably added as a liquid or in solution.
  • [0063]
    Suitable solvents include for example water, an ether such as tetrahydrofuran, a ketone such as acetone, a lower alcohol such as methanol, ethanol, or propan-2-ol, or a mixture of solvents. Other suitable solvents include toluene, acetonitrile, ethyl acetate or diethyl ether. As indicated, suitable solvents also include mixtures of the above-mentioned solvents.
  • [0064]
    An alternative source of Mesylate ion is provided by a suitably soluble base salt of methanesulfonic acid for example ammonium methanesulfonate, or the methanesulfonic acid salt of an amine, for example ethylamine or diethylamine.
  • [0065]
    The concentration of Compound (1) is preferably in the range 2 to 50% weight/volume, more preferably in the range 5 to 20%. The concentration of methanesulfonic acid solutions are preferably in the range of 5 to 150% weight/volume.
  • [0066]
    The reaction is usually carried out at ambient temperature or at an elevated temperature, for example 50-60° C. or at the reflux temperature of the solvent, although any convenient temperature that provides the required product may be employed.
  • [0067]
    Solvates, such as hydrates, of the Mesylate are prepared according to conventional procedures.
  • [0068]
    Recovery of the required compound generally comprises crystallisation from an appropriate solvent, conveniently the reaction solvent, usually assisted by cooling. For example, the Mesylate may be crystallised from an ether such as tetrahydrofuran, a nitrile such as acetonitrile, an ester such as ethyl acetate, or a lower alcohol such as propan-2-ol. An improved yield of the salt can be obtained by evaporation of some or all of the solvent or by crystallisation at elevated temperature followed by controlled cooling, optionally in stages. Careful control of precipitation temperature and seeding may be used to improve the reproducability of the product form.
  • [0069]
    Crystallisation can also be initiated by seeding with crystals of the Mesylate, especially Mesylate Form IV, or a solvate thereof but this is not essential, although it is preferred as mentioned for consistency of product form.
  • [0070]
    Compound (I) is prepared according to known procedures, such as those disclosed in EP-A-0 306 228 and WO 94/05659. The disclosures of EP-A-0 306 228 and WO 94/05659 are incorporated herein by reference.
  • [0071]
    Methanesulfonic acid is a commercially available compound.
  • [0072]
    When used herein the term “Tonset” is generally determined by Differential Scanning Calorimetry and has a meaning generally understood in the art, as for example expressed in Pharmaceutical Thermal Analysis, Techniques and Applications”, Ford and Timmins, 1989 as “The temperature corresponding to the intersection of the pre-transition baseline with the extrapolated leading edge of the transition”.
  • [0073]
    When used herein in respect of certain compounds the term “good flow properties” is suitably characterised by the said compound having a Hausner ratio of less than or equal to 1.5, especially of less than or equal to 1.25.
  • [0074]
    “Hausner ratio” is an art accepted term.
  • [0075]
    When used herein the term ‘prophylaxis of conditions associated with diabetes mellitus’ includes the treatment of conditions such as insulin resistance, impaired glucose tolerance, hyperinsulinaemia and gestational diabetes.
  • [0076]
    Diabetes mellitus preferably means Type II diabetes mellitus.
  • [0077]
    Conditions associated with diabetes include hyperglycaemia and insulin resistance and obesity. Further conditions associated with diabetes include hypertension, cardiovascular disease, especially atherosclerosis, certain eating disorders, in particular the regulation of appetite and food intake in subjects suffering from disorders associated with under-eating, such as anorexia nervosa, and disorders associated with over-eating, such as obesity and anorexia bulimia Additional conditions associated with diabetes include polycystic ovarian syndrome and steroid induced insulin resistance.
  • [0078]
    The complications of conditions associated with diabetes mellitus encompassed herein includes renal disease, especially renal disease associated with the development of Type II diabetes including diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis and end stage renal disease.
  • [0079]
    As mentioned above the compound of the invention has useful therapeutic properties: The present invention accordingly provides the Mesylate or a solvate thereof for use as an active therapeutic substance.
  • [0080]
    More particularly, the present invention provides the Mesylate or a solvate thereof for use in the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.
  • [0081]
    The Mesylate or a solvate thereof may be administered per se or, preferably, as a pharmaceutical composition also comprising a pharmaceutically acceptable carrier. Suitable methods for formulating the Mesylate or a solvate thereof are generally those disclosed for Compound (I) in the above mentioned publications.
  • [0082]
    Accordingly, the present invention also provides a pharmaceutical composition comprising the Mesylate or a solvate thereof and a pharmaceutically acceptable carrier therefor.
  • [0083]
    The Mesylate or a solvate thereof is normally administered in unit dosage form.
  • [0084]
    The active compound may be administered by any suitable route but usually by the oral or parenteral routes. For such use, the compound will normally be employed in the form of a pharmaceutical composition in association with a pharmaceutical carrier, diluent and/or excipient, although the exact form of the composition will naturally depend on the mode of administration.
  • [0085]
    Compositions are prepared by admixture and are suitably adapted for oral, parenteral or topical administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, pastilles, reconstitutable powders, injectable and infusable solutions or suspensions, suppositories and transdermal devices. Orally administrable compositions are preferred, in particular shaped oral compositions, since they are more convenient for general use.
  • [0086]
    Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well known methods in the art.
  • [0087]
    Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate. Suitable lubricants include, for example, magnesium stearate. Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.
  • [0088]
    Solid oral compositions may be prepared by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.
  • [0089]
    Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
  • [0090]
    For parenteral administration, fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle. The compound, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the active compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum.
  • [0091]
    Parenteral suspensions are prepared in substantially the same manner except that the active compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the active compound.
  • [0092]
    As is common practice, the compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.
  • [0093]
    As used herein the term ‘pharmaceutically acceptable’ embraces compounds, compositions and ingredients for both human and veterinary use: for example the term ‘pharmaceutically acceptable salt’ embraces a veterinarily acceptable salt.
  • [0094]
    The present invention further provides a method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a human or non-human mammal which comprises administering an effective, non-toxic, amount of the Mesylate or a solvate thereof to a human or non-human mammal in need thereof.
  • [0095]
    The compositions are formulated according to conventional methods, such as those disclosed in standard reference texts, for example the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Complete Drug Reference (London, The Pharmaceutical Press) and Harry's Cosmeticology (Leonard Hill Books).
  • [0096]
    Conveniently, the active ingredient may be administered as a pharmaceutical composition hereinbefore defined, and this forms a particular aspect of the present invention.
  • [0097]
    In a further aspect the present invention provides the use of the Mesylate or a solvate thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.
  • [0098]
    In the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, the Mesylate or a solvate thereof may be taken in amounts so as to provide Compound (I) in suitable doses, such as those disclosed in EP-A-0 306 228, WO 94/05659 or WO 98/55122.
  • [0099]
    No adverse toxicological effects are indicated in the above mentioned treatments for the compounds of the invention.
  • [0100]
    The following Preparations and Examples illustrate the invention but do not limit it in any way.
  • EXAMPLE 1
  • [0101]
    5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate Form I
  • [0102]
    A mixture of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (4.7 g) and acetone (180 ml) was heated to reflux to give a clear solution. A solution of methanesulfonic acid (0.83 ml) in acetone (10 ml) was added and the mixture cooled to 21° C. After standing in a sealed vessel for 5 days at 21° C. crystals of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate were collected by filtration.
  • EXAMPLE 2
  • [0103]
    5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate Form I
  • [0104]
    A mixture of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (4.4 g) and toluene (35 ml) was heated to reflux until a clear solution was observed. The solution was cooled to 90° C. and seed crystals of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy] benzyl]thiazolidine-2,4-dione methanesulfonate, prepared according to Example 1, were added followed immediately by methanesulfonic acid (0.8 ml). The mixture was cooled to 21° C. and sonicated for a period of 5 minutes and maintained at 21° C. until crystallization was complete. The mixture was sonicated for a further 5 minutes and the product collected by filtration and dried under vacuum for 5 hours to give 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate (4.4 g).
  • [0105]
    [0105]1H-NMR (d6-DMSO): consistent with 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate.
  • [0106]
    Mpt: 119-125° C.
  • [0107]
    Characterising Data for the Mesylate Form I, Recorded for the Product of Example 2
  • [0108]
    The infrared absorption spectrum of a mineral oil dispersion of the product was obtained using a Nicolet 710 FT-IR spectrometer at 2 cm-1 resolution (FIG. 1). Data were digitised at 1 cm−1 intervals. Bands were observed at: 2925, 2853, 2770, 1747, 1697, 1636, 1610, 1545, 1515, 1466, 1413, 1377, 1330, 1312, 1286, 1260, 1241, 1214, 1180, 1150, 1091, 1069, 1040, 1003, 982, 933, 887, 828, 768, 715, 670, 617, 606, 549, 526, 509 cm−1.
  • [0109]
    The infrared spectrum of the solid product was recorded using Perkin-Elmer Spectrum One FT-IR spectrometer fitted with a universal AIR accessory. Bands were observed at: 2958, 2771, 1747, 1696, 1636, 1610, 1545, 1515, 1467, 1438, 1413, 1385, 1312, 1286, 1241, 1214, 1180, 1149, 1091, 1069, 1039, 1003, 982, 933, 887, 827, 767, 736, 715, 669 cm−1.
  • [0110]
    The Raman spectrum of the product (FIG. 2) was recorded with the sample in a glass vial using a Perkin-Elmer 2000R FT-Raman spectrometer, at 4 cm-1 resolution with excitation from a Nd:YAG laser (1064 nm) with a power output of 400 mW. Bands were observed at: 3105, 3070, 3015, 2937, 1747, 1613, 1547, 1468, 1448, 1425, 1386, 1332, 1302, 1287, 1264, 1248, 1212, 1186, 1157, 1037, 982, 955, 934, 887, 849, 825, 774, 739, 721, 671, 638, 607, 548, 510, 475, 442, 421, 400, 383, 341, 299, 216 cm−1.
  • [0111]
    The X-Ray Powder Diffractogram pattern of the product (FIG. 3) was recorded using the following acquisition conditions: Tube anode: Cu, Generator tension: 40 kV, Generator current: 40 mA, Start angle: 2.0°2θ, End angle: 35.0°2θ, Step size: 0.02° 2θ, Time per step: 2.5 seconds. Characteristic XRPD angles and relative intensities are recorded in Table 1.
    TABLE 1
    Angle Rel. Intensity
    2-Theta° %
    4.6 2.4
    9.3 16.8
    11.4 1.8
    14.0 3.3
    16.8 7.0
    17.4 11.6
    18.1 24.8
    18.5 50.7
    18.8 33.7
    19.2 28.0
    19.6 10.3
    20.0 11.1
    20.7 100.0
    21.0 41.9
    21.8 35.6
    22.5 32.7
    23.2 36.2
    23.5 32.0
    24.0 13.9
    24.4 11.6
    24.7 10.7
    25.6 31.6
    26.3 15.5
    26.7 22.0
    27.2 17.9
    27.6 8.6
    28.5 17.5
    29.2 24.8
    29.8 21.2
    30.3 16.4
    31.2 11.2
    32.4 14.1
    32.8 18.5
    33.3 11.0
    34.4 11.7
  • [0112]
    Properties of the Mesylate Form I Recorded for the Product of Example 1
  • [0113]
    Solubility of the Mesylate
  • [0114]
    The solubility of the material was determined by adding water in aliquots from 0.1 to 1 ml to approximately 15 mg of drug substance until the powder had dissolved Solubility: >100 mg/ml.
  • EXAMPLE 3
  • [0115]
    5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate Form II
  • [0116]
    A mixture of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (5.0 g) and propan-2-ol (70 ml) was warmed to 70° C. with stirring under a nitrogen atmosphere. A solution of methanesulfonic acid (1.5 g) in propan-2-ol (5 ml) was added to the stirred mixture and the temperature raised to 75° C. Stirring was continued for 30 minutes to give a clear solution. The solution was cooled to 30° C. over a period of one hour and seeded with the product of Example 2. The mixture was warmed to 55° C. and stirred at this temperature for 90 minutes before cooling to 21° C. The product was collected by filtration, washed with propan-2-ol (20 ml) and dried under vacuum for 5 hours to give 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate as a white crystalline solid (5.95 g).
  • [0117]
    [0117]1H-NMR (d6-DMSO): consistent with 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate
  • [0118]
    Mpt: 115-120° C.
  • [0119]
    Characterising Data Recorded for the Product of Example 3
  • [0120]
    The infrared absorption spectrum of a mineral oil dispersion of the product was obtained using a Nicolet 710 FT-IR spectrometer at 2 cm-1 resolution (FIG. 4). Data were digitised at 1 cm−1 intervals. Bands were observed at: 1749, 1695, 1636, 1610, 1544, 1512, 1413, 1331, 1311, 1286, 1260, 1224, 1179, 1149, 1091, 1068, 1039, 1003, 994, 934, 883, 825, 769, 740, 716, 674, 617, 609, 592, 550, 524 and 509 cm−1.
  • [0121]
    The infrared spectrum of the solid product was recorded using Perkin-Elmer Spectrum One FT-IR spectrometer fitted with a universal ATR accessory. Bands were observed at: 2768, 1748, 1686, 1636, 1609, 1545, 1512, 1477, 1414, 1312, 1214, 1179, 1148, 1092, 1068, 1039, 1004, 934, 883, 826, 768, 716, 673 cm−1.
  • [0122]
    The Raman spectrum of the product (FIG. 5) was recorded with the sample in a glass vial using a Perkin-Elmer 2000R FT-Raman spectrometer, at 4 cm−1 resolution with excitation from a Nd:YAG laser (1064 nm) with a power output of 400 mW. Bands were observed at: 3104, 3068, 3016, 2938, 1749, 1611, 1582, 1547, 1467, 1448, 1424, 1387, 1331, 1300, 1287, 1264, 1245, 1212, 1185, 1156, 1067, 1037, 983, 955, 883, 850, 824, 777, 759, 740, 721, 674, 638, 609, 549, 533, 508, 476, 444, 401, 342, 299, 215 cm−1.
  • [0123]
    The X-Ray Powder Diffractogram pattern of the product (FIG. 6) was recorded using the following acquisition conditions: Tube anode: Cu, Generator tension: 40 kV, Generator current: 40 mA, Start angle: 2.0°2θ, End angle: 35.0°2θ, Step size: 0.02°2θ, Time per step: 2.5 seconds. Characteristic XRPD angles and relative intensities are recorded in Table 2.
    TABLE 2
    Angle Rel. Intensity
    2-Theta° %
    4.6 1.2
    9.2 14.2
    11.3 2.7
    13.8 3.6
    17.1 5
    18.0 23.2
    18.4 24.2
    18.7 34.1
    19.3 45.8
    20.2 11.7
    21.0 100
    21.4 22.9
    22.2 10.2
    22.6 27.3
    23.2 24
    23.5 22.8
    24.0 10.4
    24.4 12.2
    25.1 10.4
    25.5 23.5
    25.9 12.1
    26.3 9.4
    26.8 12.2
    27.2 17.4
    27.5 8.4
    28.0 11.1
    28.8 15.4
    29.0 16.2
    29.5 15.9
    30.1 7.3
    30.4 7.1
    31.1 8.2
    32.4 8.6
    32.7 12.2
    33.2 10.1
    34.0 9.6
    34.4 9.8
  • [0124]
    Properties of the Mesylate Form H Recorded for the Product of Example 3
  • [0125]
    Solubility of the Mesylate
  • [0126]
    The solubility of the material was determined by adding water in aliquots from 0.5 to 1 ml to approximately 100 mg of drug substance until the powder had dissolved
  • [0127]
    Solubility: >100 mg/ml.
  • EXAMPLE 4
  • [0128]
    5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate Form III
  • [0129]
    5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (15 g) in acetone (230 ml) was stirred and heated to reflux for 30 minutes at which point a clear solution was observed. Methanesulfonic acid (4.0 g) was added and the mixture was stirred at reflux for 5 minutes, then cooled to 40° C. and stirred until crystallisation was observed. After cooling to 21° C. the product was collected by filtration and dried under vacuum at 21° C. to provide 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate (17.3 g) as a white crystalline solid.
  • [0130]
    [0130]1H-NMR (d6-DMSO): consistent with 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate.
  • [0131]
    Mpt: 113-120° C.
  • EXAMPLE 5
  • [0132]
    5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate Form III
  • [0133]
    Methanesulfonic acid (1.69 g) was added to a suspension of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (6.0 g) and ethanol (50 ml) and the mixture was stirred and heated to give a clear solution. Diethyl ether (50 ml) was added and the mixture was heated to reflux and then cooled to 21° C. over a period of 1 hour. The product was collected by filtration, washed with diethyl ether (50 ml) and dried under vacuum for 2 hours at 21° C. to give 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate (6.40 g) as a white crystalline solid.
  • [0134]
    Characterising Data for the Mesylate Form III Recorded for the Product of Example 4
  • [0135]
    The infrared absorption spectrum of a mineral oil dispersion of the product was obtained using a Nicolet 710 FT-IR spectrometer at 2 cm-1 resolution (FIG. 7). Data were digitised at 1 cm−1 intervals. Bands were observed at: 3113, 2926, 2853, 2761, 1747, 1693, 1647, 1610, 1546, 1511, 1466, 1418, 1332, 1304, 1260, 1238, 1206, 1185, 1157, 1097, 1040, 1027, 1010, 983, 902, 819, 773, 739, 722, 713, 655, 618, 603, 559, 545, 521, 507 cm−1.
  • [0136]
    The infrared spectrum of the solid product was recorded using Perkin-Elmer Spectrum One FT-IR spectrometer fitted with a universal ATR accessory. Bands were observed at: 2918, 2754, 1747, 1692, 1646, 1610, 1546, 1511, 1468, 1439, 1416, 1332, 1303, 1258, 1237, 1205, 1182, 1155, 1039, 982, 902, 819, 772, 739, 712, 668, 654 cm1.
  • [0137]
    The Raman spectrum of the product (FIG. 8) was recorded with the sample in a glass vial using a Perkin-Elmer 2000R FT-Raman spectrometer, at 4 cm-1 resolution with excitation from a Nd:YAG laser (1064 nm) with a power output of 400 mW. Bands were observed at: 3099, 3008, 2935, 1747, 1610, 1546, 1441, 1386, 1332, 1266, 1205, 1179, 1079, 1042, 985, 920, 820, 776, 740, 657, 636, 618, 603, 557, 544, 522, 469, 407, 392, 339, 226 cm−1.
  • [0138]
    The X-Ray Powder Diffractogram pattern of the product (FIG. 9) was recorded using the following acquisition conditions: Tube anode: Cu, Generator tension: 40 kV, Generator current: 40 mA, Start angle: 2.0°2θ, End angle: 35.0° 2θ, Step size: 0.02° 2θ, Time per step: 2.5 seconds. Characteristic XRPD angles and relative intensities are recorded in Table 3.
    TABLE 1
    Angle Rel. Intensity
    2-Theta° %
    4.5 9.4
    7.7 16.1
    10.9 21.4
    12.5 4.7
    13.3 38.6
    14.6 6.2
    14.8 7.9
    15.4 9
    16.9 100
    17.2 57
    17.9 46.9
    18.2 17.8
    18.7 10.3
    18.9 8.6
    20.4 8.2
    20.9 9.3
    22.1 18.9
    22.5 34
    22.7 42.6
    23.2 38.3
    23.5 36.1
    24.7 28.3
    25.6 16.2
    25.9 24.6
    26.2 36.3
    26.8 15.1
    27.8 16.6
    29.1 16.8
    29.8 16.6
    30.5 12.2
    31.1 9.1
    31.7 11
    32.0 14
    32.9 11.4
    34.0 9
    34.5 13.2
  • [0139]
    Properties of the Mesylate Form III recorded for the product of Example 4
  • [0140]
    Solubility of the Mesylate
  • [0141]
    The solubility of the material was determined by adding water in aliquots from 0.5 to 1 ml to approximately 100 mg of drug substance until the powder had dissolved
  • [0142]
    Solubility: >100 mg/ml.
  • EXAMPLE 6
  • [0143]
    5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate Form IV
  • [0144]
    A solution of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (3.0 g) in tetrahydrofuran (30 ml) was stirred and heated to 50° C. Methanesulfonic acid (0.54 ml) was added and the mixture heated to reflux and seeded with the product of Example 2. The stirred mixture was cooled to 21° C. over a period of approximately 1 hour and the product was collected by filtration, and dried under vacuum to give 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate as a white crystalline solid (3.32 g).
  • [0145]
    [0145]1H-NMR (d6-DMSO): consistent with 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate.
  • [0146]
    Melting Point: 145.8° C.
  • EXAMPLE 7
  • [0147]
    5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate Form IV
  • [0148]
    Methanesulfonic acid (2.3 ml) was added to a stirred suspension of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (12.0 g) in ethanol (100 ml) at 21° C. The reaction mixture was heated to reflux for 30 minutes then cooled to 21° C. Diethyl ether (100 ml) was added and the reaction heated to reflux for 1 hour, then cooled to 21° C. The reaction was heated to reflux, diethyl ether (50 ml) was added and stirred for 30 minutes, cooled to 21° C. over approximately 1 hour, then stirred for 16 hours at 21° C. The product was collected by filtration and dried under vacuum to afford 5-[4-[2-N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate (14.8 g) as a white crystalline solid.
  • EXAMPLE 8
  • [0149]
    5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate Form IV
  • [0150]
    A solution of methanesulfonic acid (0.55 g) in tetrahydrofuran (10 ml) was added to a stirred solution of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione (2.50 g) in tetrahydrofuran (50 ml) at 21° C. The mixture was stirred for 5 minutes and then cooled to 4° C for a period of 16 hours. The product was collected by filtration, washed with tetrahydrofuran (10 ml) and dried under vacuum at 21° C. for 3 hours to give 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate (2.95 g) as a white crystalline solid.
  • EXAMPLE 9
  • [0151]
    5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate Form IV
  • [0152]
    A suspension of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (3.0 g) in acetonitrile (60 ml) was heated to 60° C. Methanesulfonic acid (0.54 ml) was added and the mixture stirred at 60° C. to give a clear solution. After cooling to 21° C. the solvent was evaporated under reduced pressure, propan-2-ol (20 ml) added to the residue and the mixture stirred at 21° C. to give a white suspension. The product was collected by filtration, washed with propan-2-ol and dried under vacuum for 5 hours to give 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate (3.37 g) as a white crystalline solid.
  • EXAMPLE 10
  • [0153]
    5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate Form IV
  • [0154]
    Methanesulfonic acid (0.54 ml) was added to a mixture of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (3.0 g) and ethyl acetate (60 ml) and the reaction mixture stirred and heated to reflux to give a suspension. After cooling to 21° C. the product was collected by filtration, washed with ethyl acetate (10 ml) and dried under vacuum for 16 hours to give 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate (3.73 g) as a white crystalline solid.
  • EXAMPLE 11
  • [0155]
    5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate Form IV
  • [0156]
    A mixture of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (12.0 g) and propan-2-ol (360 ml) was stirred and heated to reflux for 10 minutes at which point a clear solution was observed. Methanesulfonic acid (4.04 ml) was added and the stirred reaction mixture cooled to 75° C., seeded with the product of Example 6 and then cooled to 21° C. over a period of approximately 1 hour. The solid was collected by filtration, washed with propan-2-ol (50 ml) and dried under vacuum for 16 hours to give 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate (13.8 g) as a white crystalline solid.
  • [0157]
    Characterising Data for the Mesylate Form IV Recorded for the Product of Example 6
  • [0158]
    The infrared absorption spectrum of a mineral oil dispersion of the product was obtained using a Nicolet 710 FT-IR spectrometer at 2 cm−1 resolution (FIG. 10). Data were digitised at 1 cm−1 intervals. Bands were observed at: 3115, 2926, 2854, 2771, 1747, 1702, 1646, 1617, 1586, 1549, 1512, 1459, 1423, 1377, 1336, 1314, 1303, 1243, 1155, 1109, 1040, 1008, 911, 830, 816, 775, 759, 736, 714, 662, 620, 600, 552, 531, 505 cm−1.
  • [0159]
    The infrared spectrum of the solid product was recorded using Perkin-Elmer Spectrum One FT-IR spectrometer fitted with a universal ATR accessory. Bands were observed at: 2771, 1747, 1698, 1646, 1613, 1587, 1550, 1512, 1478, 1451, 1422, 1388, 1335, 1314, 1239, 1153, 1110, 1032, 1008, 963, 911, 829, 816, 774, 758, 736, 713, 660 cm−1.
  • [0160]
    The Raman spectrum of the product (FIG. 11) was recorded with the sample in a glass vial using a Perkin-Elmer 2000R FT-Raman spectrometer, at 4 cm−1 resolution with excitation from a Nd:YAG laser (1064 nm) with a power output of 400 mW. Bands were observed at: 3107, 3063, 3007, 2933, 1748, 1700, 1613, 1587, 1549, 1452, 1422, 1389, 1338, 1313, 1289, 1264, 1248, 1209, 1183, 1150, 1112, 1084, 1042, 1010, 990, 963, 916, 840, 776, 741, 720, 665, 636, 620, 601, 552, 529, 498, 469, 430, 412, 399, 389, 344, 337, 298, 263, 228 cm−1.
  • [0161]
    The X-Ray Powder Diffractogram pattern of the product (FIG. 12) was recorded using the following acquisition conditions: Tube anode: Cu, Generator tension: 40 kV, Generator current: 40 mA, Start angle: 2.0°2θ, End angle: 35.0°2θ, Step size: 0.02°2θ, Time per step: 2.5 seconds. Characteristic XRPD angles and relative intensities are recorded in Table 4.
    TABLE 4
    Angle Rel. Intensity
    2-Theta° %
    6.2 3.2
    9.2 12.1
    10.8 10.9
    11.4 4.2
    11.9 9.7
    12.4 8.2
    13.3 34
    14.5 4.7
    15.0 2.5
    15.9 7.9
    16.8 100
    17.6 2.3
    18.4 11.3
    18.6 43.8
    19.0 3.5
    19.8 12.1
    20.3 7.5
    21.2 32.2
    21.6 33.6
    21.9 21.1
    22.1 14
    22.4 30.1
    22.7 80.2
    23.0 24.6
    23.9 4.7
    24.5 8.8
    25.0 4.8
    25.6 7.5
    26.1 8.9
    26.6 19.1
    27.1 7.1
    27.6 7.8
    28.0 21
    29.3 5.3
    29.9 14.6
    30.3 5.9
    31.4 12.6
    31.6 6.5
    32.1 11.2
    33.1 10
    33.4 3
  • [0162]
    The solid-state NMR spectrum of the product (FIG. 13) was recorded on a Bruker AMX360 instrument operating at 90.55 MHz: The solid was packed into a 4 mm zirconia MAS rotor fitted with a Kel-F cap and rotor spun at ca. 10 kHz. The 13C MAS spectrum was acquired by cross-polarisation from Hartmann-Hahn matched protons (CP contact time 3 ms, repetition time 15 s) and protons were decoupled during acquisition using a two-pulse phase modulated (TPPM) composite sequence. Chemical shifts were externally referenced to the carboxylate signal of glycine at 176.4 ppm relative to TMS and were observed at: 37.4, 40.1, 49.9, 55.9, 67.8, 111.2, 115.6, 118.9, 130.7, 131.4, 134.3, 140.3, 141.5, 153.0, 157.2, 157.7, 171.8, 176.7 ppm.
  • [0163]
    Properties of the Mesylate Form IV
  • [0164]
    Solid State Stability of the Mesylate Form IV Recorded for the Product of Example 11
  • [0165]
    The solid state stability of the drug substance was determined by storing approximately 1.0 g of the material in a glass bottle at a) 40° C./75% Relative Humidity (RH), open exposure, for 1 month and b) at 50° C., closed, for 1 month. The material was assayed by HPLC for final content and degradation products in both cases.
  • [0166]
    a) 40° C./75% RH: No significant degradation observed (HPLC assay 98% initial).
  • [0167]
    b) 50° C.: No significant degradation observed (HPLC assay 100% initial).
  • [0168]
    Solubility of the Mesylate Form IV Recorded for the Product of Example 11
  • [0169]
    The solubility of the material was determined by adding water in aliquots from 1 to 1000 ml to approximately 100 mg of drug substance until the powder had dissolved. The visual solubility was confirmed by an HPLC assay of a saturated solution.
  • [0170]
    Solubility: >100 mg/ml.
  • [0171]
    Flow Properties of the Mesylate Form IV Recorded for the Product of Example 11
  • [0172]
    The ratio between the bulk density and the tapped bulk density (Hausner Ratio) of the Mesylate was determined using standard methods (“Pharmaceutics—The Science of Dosage Form Design”, editor M. Aulton, 1988, published by: Churchill Livingstone).
  • [0173]
    Hausner Ratio: 1.2
  • [0174]
    Tonset of the Mesylate Form IV Recorded for the Product of Example 11
  • [0175]
    The Tonset of the drug substance was determined by Differential Scanning Calorimetry using a Perkin-Elmer DSC7 apparatus.
  • [0176]
    Tonset (10° C./minute, closed pan): 147° C.
  • [0177]
    Melting Range of the Mesylate Form IV Recorded for the Product of Example 7
  • [0178]
    The melting range of the Mesylate was determined according to the method described in the U.S. Pharmacopoeia, USP 23, 1995, <741> “Melting range or temperature, Procedure for Class Ia”, using a Buchi 545 melting point instrument.
  • [0179]
    Melting range: 148.9-150.3° C.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US5741803 *Jun 5, 1995Apr 21, 1998Smithkline Beecham PlcSubstituted thiazolidinedionle derivatives
US5910592 *Jul 14, 1997Jun 8, 1999Smithkline Beecham PlcSubstituted thiazolidinedione derivatives
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US7435741May 9, 2006Oct 14, 2008Teva Pharmaceutical Industries, Ltd.2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US7632841Dec 15, 2009Teva Pharmaceutical Industries, Ltd.2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US7786133Aug 31, 2010Nektar TherapeuticsChemically modified small molecules
US8034825Oct 11, 2011Nektar TherapeuticsChemically modified small molecules
US8067431Feb 22, 2010Nov 29, 2011Nektar TherapeuticsChemically modified small molecules
US9012469Sep 29, 2011Apr 21, 2015Astrazeneca AbCrystalline naloxol-peg conjugate
US9149539Mar 11, 2015Oct 6, 2015Astrazeneca AbCrystalline naloxol-PEG conjugate
US9388104Apr 8, 2014Jul 12, 2016Nektar TherapeuticsChemically modified small molecules
US20050136031 *Dec 16, 2004Jun 23, 2005Bentley Michael D.Chemically modified small molecules
US20060182692 *Jan 30, 2006Aug 17, 2006Fishburn C SChemically modified small molecules
US20070265313 *Oct 20, 2006Nov 15, 2007Teva Pharmaceutical Industries, Ltd.2-N butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US20100081695 *Apr 1, 2010Teva Pharmaceutical Industries, Ltd.2-N-{5-[ [4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione) butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US20100210676 *Feb 22, 2010Aug 19, 2010Nektar TherapeuticsChemically Modified Small Molecules
US20100305147 *Dec 2, 2010Nektar TherapeuticsChemically modified small molecules
Classifications
U.S. Classification514/342, 546/269.7
International ClassificationA61P3/00, C07D417/12, A61K31/4439, A61P3/10
Cooperative ClassificationC07D417/12
European ClassificationC07D417/12
Legal Events
DateCodeEventDescription
Dec 4, 2003ASAssignment
Owner name: SMITHKLINE BEECHAM P.L.C., GREAT BRITAIN
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CRAIG, ANDREW SIMON;HO, TIM CHIEN TING;MILLAN, MICHAEL;AND OTHERS;REEL/FRAME:014175/0937;SIGNING DATES FROM 20031118 TO 20031202